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Cervid herpesvirus 2 (CvHV2) is an alphaherpesvirus found in Rangifer subspecies throughout 
most of the circumpolar Arctic and the causative agent of infectious keratoconjunctivitis (IKC) 
in semi-domesticated Eurasian tundra reindeer (Rangifer tarandus tarandus). IKC occurs as 
regular outbreaks, affecting dozens of reindeer in a herd, and is most common and severe among 
calves and young animals. IKC often appears as mild clinical signs from which the animals often 
recover, but the disease can progress to more advanced stages where the eye is severely 
damaged, resulting in blindness or death. Development of an antiviral therapy for CvHV2 could 
improve animal welfare conditions and reduce economic losses within reindeer herding industry 
in Fennoscandia. To our knowledge, only one pilot study has previously tested the effectiveness 
of antiviral drugs against CvHV2 and indicated that the nucleoside analog drug Acyclovir, 
commonly used as an antiherpetic treatment in humans and other species, was not successful 
inhibiting viral replication. This master’s study aimed to further investigate the effect of antiviral 
drugs against CvHV2 by testing Ganciclovir and Cidofovir, and to evaluate their potential use as 
part of a treatment for IKC in semi-domesticated reindeer in Fennoscandia. An in vitro 
experiment which used Madin-Darby bovine kidney (MDBK) cell cultures was used as a 
preliminary model for natural CvHV2 infection in reindeer. A negative dose-response 
relationship was found for both Ganciclovir and Cidofovir, however, neither drug was able to 
completely inhibit the viral replication even at the highest drug concentrations and lowest viral 
titers tested. These findings indicate that both drugs are tentative candidates for the development 
of an antiviral treatment for CvHV2, but further studies to attempt to increase the therapeutic 
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1.1 HOST: Rangifer tarandus 
With an estimated global population of  three million animals, Rangifer tarandus, known as 
either caribou or reindeer, is the most populous cervid in the circumpolar Arctic and Subarctic 
zones (Gunn 2016). The majority of Rangifer live in North America, with smaller populations 
distributed throughout Fennoscandia, Russia, Iceland, Svalbard, Greenland. In North America, 
all subspecies are wild and free-ranging caribou, with the exception of a small population of 
semi-domesticated Eurasian tundra reindeer, of Russian origin, living in Alaska (Lantis 1950). 
Rangifer in Fennoscandia, Russia, Iceland, Greenland are predominantly semi-domesticated 
reindeer, with small, localized populations of wild reindeer and caribou. The taxonomy of 
Rangifer subspecies has been debated, but it is generally accepted that there are seven extant 
subspecies of Rangifer: Woodland caribou (R. t. caribou), Canadian barren-ground caribou (R. t. 
groenlandicus), Peary caribou (R. t. pearyi), Alaska tundra or Porcupine caribou (R. t. granti), 
Eurasian tundra reindeer (R. t. tarandus), wild forest reindeer (R. t. fennicus), and Svalbard 
reindeer (R. t. platyrhynchus) (Banfield 1961).  
 
While Rangifer are not considered an endangered species, the total global population is thought 
to be declining significantly, and certain subspecies and populations are protected due to reduced 
size and habitat changes (Valkenburg et al. 1996; McLoughlin et al. 2003; Vors and Boyce 2009;  
Hervieux et al. 2013). It is estimated that Rangifer have declined by 2,000,000 individuals or 
40% of the total global population in the last 10-30 years (Gunn 2016). Current hypotheses  of 
the cause of these declines include effects related to climate change, such as phenology shifts, 
increases in extreme weather events, and range shifts of other species, as well as anthropogenic 
causes like habitat fragmentation related to development in rural areas (Cameron et al. 2005; 
Schaefer 2003; Vors and Boyce 2009; Uboni et al. 2016). Declines or extinctions could lead to 
substantial monetary and cultural losses for circumpolar communities, as well as ecosystem 







Figure 1: Circumpolar distribution of Rangifer herds through the Arctic, illustrating the current 
dynamics of wild populations, overlaid with the geographic regions of reindeer husbandry 




1.1.1 Biology and Ecology  
All Rangifer subspecies have homologous adaptations for survival in the harsh and variable 
environmental conditions of the Arctic and sub-Arctic. These include broad, four-toed hooves 
that assist in walking and digging for forage in deep snow, and a pelage composed of a dense 
underlayer and an outer coat of long, hollow guard hairs, that trap air close to the body aiding 
both heat retention and flotation when swimming (Blix 2005). Both sexes have antlers, with 
differing seasonality corresponding to the energetically intensive reproductive periods of the year 
for either sex. Males typically have larger antlers, grown throughout the summer and used to 
compete with other males during autumn mating, while females retain their antlers through the 
winter season, giving them a foraging advantage while gestating and shed them in the spring 
after their calves are born (Palmer 1934).  
 
Rangifer subspecies are diverse in other aspects their morphology due to local adaptations during 
the glaciation period of the Pleistocene (Yannic et al. 2013). Forest dwelling subspecies typically 
have longer, thinner legs, better adapted to outrunning predators (Nieminen and Helle 1980; 
Klein et al. 1987). In contrast, the high Arctic subspecies, Svalbard reindeer and Peary caribou, 
have exceptionally short-legs and a stout abdomen, having evolved in predator-free island 
environments and thus adapted to more sedentary, energy-conserving movements (Gravlund et 
al. 1998).  
 
Rangifer live in regions of the world with low plant diversity and productivity, where forage is 
covered by snow and ice most of the year. Because of this, forage availability is a significant 
ecological pressure in Rangifer and can determine population distribution and migration patterns. 
Diet can vary substantially between seasons and regions, but typical diet items include grasses, 
sedges, lichens, mushrooms and woody shrubs (Bergerud 1972; Rominger and Oldemeyer 1990). 
Lichens are a particularly important food item for semi-domesticated reindeer and can compose a 
majority of their diet in the winter (Inga 2007). 
 
With the exception of Svalbard reindeer, wild Rangifer populations have long seasonal 
migrations between winter and summer ranges. The Porcupine caribou herd in Alaska migrates 
more than 5000km (Fancy 1989). These migrations are driven by forage availability, weather 
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conditions, and avoidance of predators and insect harassment. Winter movements are typically 
related to depth of snow and ability to reach snow covered forage, while summer movements can 
be affected by avoidance of parasitic insects (Bevanger and Jordhoy 2004). Semi-domesticated 
reindeer are not allowed to migrate freely as wild Rangifer populations do but are still herded 
seasonally between summer and winter pastures (Pape and Loffler 2012). 
 
1.1.2 Semi-Domesticated Reindeer in Norway 
Semi-domesticated reindeer are unique among all Rangifer populations because they are free-
ranging but herded and actively managed by humans. Reindeer have been utilized by the Saami, 
the indigenous people of Fennoscandia, and others for thousands of years through hunting, but as 
early as 800 A.D., the Saami began domestication of reindeer (Bjorklund 2012). Reindeer 
husbandry in Fennoscandia began with the herding of small groups of reindeer (<25 animals) by 
single families (Hultblad 1968). Over time, these reindeer herds became bigger and family 
groups started to work collectively in traditional Siida units in order to manage larger numbers of 
animals. Reindeer husbandry is thought to have become a primary livelihood for Saami people in 
Norway in the early 18th century (Leem 1975).   
 
Reindeer husbandry continues to be an economically and culturally significant activity for Saami 
people and others in present-day Fennoscandia. In 2017 there were an estimated 650,000 semi-
domestic reindeer in Norway, Sweden, and Finland (Landbruksdirektoratet 2017). The annual 
revenue of reindeer herding can vary dramatically depending on the specific herding conditions 
of each year, but the value of semi-domestic reindeer in Fennoscandia ranged from  
338-345 million Norwegian kroner (NOK) in 2015-2016 (Landbruksdirektoratet 2017).  
 
In Norway, there are 6 designated reindeer pasture areas, covering approximately 140,000 km2 or 
nearly 40% of the surface area of the country (Ulvevadet and Klokov 2004). Only Saami people 
are allowed to own reindeer in Norway, except within small ‘Concession Areas’ (Tamreinlag) in 
southern Norway, outside of the designated reindeer pasture areas. 
 
 Traditional earmarks of a unique pattern of knife cuts or modern electronic microchips, are used 
to identify ownership of each reindeer. Herds are gathered 1-2 times annually for ear-marking or 
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tagging, anti-parasite treatment, and slaughter. Saami herders use all-terrain vehicles, 
snowmobiles, and helicopters to direct the movement of a herd during controlled seasonal 
migrations. Due to habitat fragmentation and issues of land ownership and pasture rights, some 
reindeer herds are transported in trucks from one seasonal pasture area to another (Vistnes and 
Nellemann 2007). 
 
Yearly loses of semi-domesticated reindeer can be fairly high with 18-20% reported lost by 
herders (Nybakk et al 2002; Landbruksdirektoratet 2017). Starvation, predation by large 
carnivores, extreme weather events, and accidents, including vehicle strikes, are all common 
causes of reindeer loss (Nybakk et al 2002, Tveraa et al. 2014). In the past, disease outbreaks 
have been a serious challenge to reindeer herding, killing thousands of animals, however current 
health conditions of reindeer in Norway are favorable for survival and meat production (Tryland 
2012). Outbreaks of infectious keratoconjunctivitis and contagious ecthyma can occur, but do not 
cause significant mortality annually (Tryland et al 2001a; Tryland et al. 2009). Semi-
domesticated reindeer are also impacted by a wide variety of parasites including helminths, 
arthropods, and protozoa (Josefsen et al. 2014). Warble flies and the nematodes Setaria tundra 
and Elaphostrongylus rangiferi are examples of the most commonly found parasites (Helle 1980; 
Handeland and Slettbakk 1994; Laaksonen et al. 2009; Åsbakk et al. 2014) 
 
It is anticipated that the impacts of disease among semi-domesticated reindeer may become more 
severe with the progression of climate change (Tryland 2012). In addition to possible exposure to 
novel parasites and pathogens, climate change conditions such as increased mid-winter freeze-
thaw cycles and rain on snow events may cause reindeer to become more susceptible to enzootic 
diseases due to starvation related stress (Tryland 2012). The formation of ice on top of snow or 
buried vegetation following episodes of above-freezing temperatures in winter, significantly 
reduces forage availability for reindeer (Tyler 2010; Forbes et al. 2016). Increased levels of 
glucocorticoids caused by emaciation can lead to immunosuppression and higher incidence of 
disease (Nathan et al. 1977, Coutinho and Chapman 2011). Such conditions could leave Rangifer 





Due to increased rain on snow events and decreased winter forage, it has also become necessary 
for some herders to provide supplemental feed to maintain their herd overwinter, which may 
create further health problems. Aggregation of animals at feeding stations can lead to increased 
disease transmission due to increased herd density and hygiene challenges such as dirty corrals 
or airborne feed particulates (Rehbinder and Nilsson 1995). Necrobacillosis, parapoxvirus 
infections, pasteurellosis, and infectious keratoconjunctivitis are diseases of particular concern 
under such circumstances (Kummeneje 1976; Rehbinder and Nilsson 1995; Tryland et al. 2001b, 
Tryland et al. 2009; Handeland et al. 2010).  
 
1.2 DISEASE: Infectious Keratoconjunctivitis 
 
Infectious keratoconjunctivitis (IKC) is a multifactorial, transmissible eye disease common 
among both domestic animals and wildlife. IKC does not typically cause high mortality as 
infections are often limited to subclinical or mild clinical signs, but it can result in significant 
morbidity due to its highly infectious nature, particularly among herd species where animal 
density can increase transmission (Bergman 1912). Infectious bovine keratoconjunctivitis (IBK) 
is considered the most important ocular diseases among bovines and can result in significant 
economic losses due to emaciation and loss of productivity in meat or dairy production animals 
(Angelos 2010; Angelos 2015). IKC has also been well documented in a variety of wild 
ruminants including moose, alpine chamois, ibex, red deer, mule deer, pronghorn antelope, 
caribou, and semi-domesticated reindeer (Dubay et al. 2000; Giacometti et al. 2002; Gortazer et 
al. 1998; Evans et al. 2008; Bergman 1912; Thorne 1982). 
 
IKC was first documented in semi-domesticated reindeer at the beginning of the 20th century, 
and continues to occur throughout Fennoscandia in sporadic outbreaks primarily affecting calves, 
which often display the most severe clinical signs (Bergman 1912; Tryland et al. 2009). While 
no scientific study has reported the current prevalence of IKC in Norway, a questionnaire survey 
of reindeer herders in Norway and Sweden showed that IKC is likely common as 55% (n=63) 
reported observing IKC in their animals within the previous year (Tryland et al. 2016). Herders 
additionally responded that they most often observed IKC affecting only 1-5 animals at a time, 
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but there are also cases of IKC causing larger outbreaks (Rehbinder and Nilsson 1995; Tryland et 
al. 2009).  
 
Staining  and clumping of the fur below the eye caused by increased lacrimation and pus is often 
the first clinical sign (Fig. 3A) observed by herders during an outbreak of IKC (Tryland et al. 
2017). This may occur either unilaterally or bilaterally (Winqvist and Rehbinder 1973). During 
the progress of a mild to moderate infection, inflammation of the conjunctiva and cornea occurs, 
and the eye may appear cloudy, opaque or blueish due to corneal edema (Fig. 3B) (Winqvist and 
Rehbinder 1973). In the final stages panophthalmitis occurs accompanied by accumulation of 
periorbital edema, blood and purulent secretions (Fig. 3C). Ocular ulcers can lead to loss of the 
lens or other eye structures (Fig. 3D) (Rehbinder 1977). At the early stages of IKC, many 
animals spontaneously recover without permanent ocular damage, but when the disease 
progresses to the most severe clinical signs, blindness is likely to occur (Ryser-Degiorgis et al. 
2009; Tryland et al. 2009). Long-term survival of a partially or fully blind reindeer is critically 
impacted as the ability to locate food and avoid environmental obstacles and predators 
diminishes with the loss of sight (Tryland et al. 2017). Even early stages of IKC are likely to be 
highly painful for affected animals, and these infections are of concern from the perspective of 
both animal welfare and economic losses for reindeer herders. Indirect mortality can also occur 
because herders may choose to slaughter infected animals as a means to control the spread of an 








Figure 2. Clinical signs of infectious keratoconjunctivitis in semi-domesticated reindeer at 
increasing stages of the disease: (A) conjunctivitis with increased lacrimation and purulent 
secretions, (B) corneal opacity caused by corneal edema. (C) severe conjunctivitis with 
periorbital edema, purulent secretions and bleeding, (D) severe corneal ulceration that led to 







IKC is considered a multifactorial disease because both environmental conditions and presence 
of pathogens affect the development of the disease. UV exposure, dust and other airborne 
particles can irritate the fibrous tunic and conjunctiva, leaving the eye more vulnerable to 
colonization by pathogens (Rehbinder et al. 1978). A variety of pathogens have been associated 
with IKC in wild ruminants including species of the bacterial families Moraxellaceae, 
Mycoplasmataceae and Chlamydiaceae, and a diversity of alphaherpesviruses (Rehbinder et al. 
1975; Nettleton et al. 1986; Tryland et al. 2009; Smits et al. 2013; Giangaspero et al. 2010; 
Dubay 2000). Because of the multifactorial nature of IKC, it was initially unclear which 
infectious agent was the cause for the development of IKC in reindeer. During a severe outbreak 
of IKC in 1993 among Swedish semi-domesticated reindeer, bacteriology of eye swab samples 
and serological tests detected the presence of several bacterial species in the eyes, including 
Moraxella sp. and Pasteurella multocida (Rehbinder and Nilsson 1995).  
 
Cervid herpesvirus 2 (CvHV2) was determined to be the primary pathogen in a 2009 outbreak of 
IKC in Norwegian semi-domesticated reindeer (Tryland et al. 2009). Both affected and 
unaffected animals were seropositive for CvHV2 antibodies, but the virus could only be isolated 
from the eyes of reindeer with active infections (Tryland et al. 2009). Viral activity of isolates 
was investigated by assessing virulence in cell culture. Severity of damage to the culture cells, 
known as cytopathic effect (CPE), increased with severity of clinical signs in sampled reindeer, 
apart from those with the most advanced IKC infections. In the most advanced IKC cases, 
CvHV2 could not be detected and bacteria, including Moraxella sp., appeared to cause secondary 
infections. CvHV2 was further implicated in IKC occurrence during an experimental inoculation 
study with CvHV2, Moraxella bovoculi, or both CvHV2 and M. bovoculi in semi-domesticated 
reindeer calves (Tryland et al. 2017). Calves inoculated with CvHV2 or both, CvHV2 and M. 
bovoculi, rapidly developed severe cases of IKC, while those inoculated only with M. bovoculi 
did not develop any clinical signs. It is concluded through these two studies that while IKC may 





1.3 PATHOGEN: Cervid Herpesvirus 2 
 
1.3.1 Characterization of Alphaherpesviruses 
Herpesviridae is a large family of enveloped, double-stranded DNA (dsDNA) viruses with 
complex genomes, capable of establishing life-long latent infections in mammals, birds and 
reptiles. The genomes of herpesviruses are large, with 125-290 kb containing 60-120 genes and 
form a torus configuration within the viral capsid when not undergoing replication (Furlong et al. 
1972; Davison et al. 2009). The virion is composed of an icosahedral capsid core containing the 
double-stranded DNA genome, surrounded by a protein matrix called the tegument, and enclosed 
by a lipid bilayer envelope, embedded with surface glycoproteins (Fig. 3). The capsid of the 
virion is in an icosahedral shape approximately 100-150nm in diameter with 162 capsomeres 
(Pellett and Roizman 2006). Between the capsid and viral envelope, the tegument is an 
amorphous and asymmetrically thick mass of proteins and enzymes utilized in the early stages of 
host cell infection and protect against the cell’s initial immune defenses (Jenkins and Hoffman 
2000). Lastly, the viral envelope is composed of proteins originating from the endoplasmic 
reticulum of the host cell and contains a variety of viral glycoproteins responsible for the virion’s 












Figure 3. Structure of herpesvirus virion, highlighting the viral envelope, surface glycoproteins, 





Herpesviridae is divided into three subfamilies: alphaherpesvirinae (-herpes), 
betaherpesvirinae (-herpes), and gammaherpesvirinae (-herpes). Taxonomy of the subfamilies 
is  based on genetic and biological characteristics including host cell tropism, length of 
reproductive cycle, behavior in cell culture and ability to establish latent infections in sensory 
nerve ganglia or other tissues in the body (Davison et al 2009; Knowles 2011). 
Alphaherpesviruses, referred to as neurotropic herpesviruses, infect a large variety of hosts, 
exhibit a wide range of tissue tropisms, replicate rapidly, and establish latency in sensory nerve 
ganglia (Knowles et al. 2011). Human herpes simplex viruses 1 and 2 (HSV1/HSV2) and 
varicella zoster virus (VZV) are common alphaherpesviruses that effect humans (Davison et al. 
2009). A variety of alphaherpesvirus infect domestic and wild ruminants such as bovine 
herpesvirus 1 (BoHV1), caprine herpesvirus 1 (CpHV1), bubaline herpesvirus 1 (BuHV1) and 
cervid herpesviruses 1 (CvHV1) and 2 (CvHV2) (Thiry et al. 2006). 
 
Alphaherpesviruses undergo rapid replication in the host cell nucleus during a lytic infection 
(Roismann et al. 1992; Knowles et al. 2011). The virion utilizes a variety of glycoproteins (gC, 
gD, gB and gH) to quickly attach to the cellular membrane, fuse, and enter a host cell (Tikoo et 
al. 1995). Immediately after entry, the virion signals for cessation of host cell protein production 
and the intact capsid moves along the cytoskeleton to inject the viral genome into the host 









Figure 4. Organization of herpesvirus genome: Two segments, the long unique unit (UL) and the 
short unique unit (US), each surrounded by a set of a terminal (TRL/TRS) and an internal repeat 
sequence (IRL/IRS). Gene classes are described in the figure legend. Adapted with permission 
from ViralZone 2009 – Swiss Institute for Bioinformatics (www.expasy.org/viralzone). 
 
The dsDNA linear molecule is composed of two main segments (Fig. 4): a long unique unit (UL) 
and a short unique unit (US), each capped by two internal repeat sequences, an internal repeat 
(IR) and a terminal repeat (TR) (Schwyzer and Ackermann. 1996). Viral gene expression is 
divided into three classes: immediate-early (IE), early (E), and late (L). As soon as the genome is 
injected into the nucleus of the host cell, IE genes code for creation of regulatory proteins, to 
take over control of the host cell’s replication mechanisms (Thiry et al. 2006; Thellman and 
Trizenberg 2017).  E genes produce enzymes, such as viral kinases and DNA polymerase, and 
increase the available pool of nucleotides (Levings et al. 2013). Lastly L genes function to 




Immediate-early genes (IE) 
Early genes (E) 
Late genes (L) 
Latency genes (LATs) 
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When the viral DNA is transcribed by cellular RNA polymerase into mRNA, it moves into the 
cytoplasm for translation (Fields et al. 2001). The proteins produced during translation disperse 
into the nucleus, endoplasmic reticulum, and cytoplasm. In the nucleus, the viral DNA is shaped, 
and capsid structural proteins are formed. The tegument and envelope are initially formed as 
transformed sections of the cell’s nuclear envelope. Budding is triggered when the nucleocapsids 
bind to this section of the envelope. Once released from the nucleus, the enveloped viral particles 
gather in the endoplasmic reticulum before being expelled from the cell by exocytosis. 
 
The most characteristic aspect of the Herpesviridae family is the ability to establish latency after 
a primary lytic infection. In a latent alphaherpesvirus infection, virions travel from the site of the 
primary infection, usually epithelial cells of mucosal tissues, into the sensory ganglia neurons 
(Engels and Ackermann 1986; Jones et al. 2006). The virions enter the neuron cell in the same 
manner as during active replication: glycoproteins bind to the cell surface and the virion fuses 
with the membrane until the nucleocapsid is able to enter the cell. Once inside the neural cell, the 
virion injects its genome in the nucleus of the cell and activates a small set of genes called 
latency associated transcript (LATs). LATs maintain latency by suppressing IE and E genes and 
protecting the cell from apoptosis (Jones et al. 2006). The specific mechanism viral reactivation 
and return to a lytic infection is not well-known. In ruminants, alphaherpesvirus reactivation can 
occur either under conditions of physiological stress such as starvation or mating, or 
spontaneously (Engels and Ackermann 1996; Thiry et al. 2006) 
 
1.3.2 Prevalence and Detection of CvHV2 
Cervid herpesvirus 2 is an alphaherpesvirus known to infect reindeer and caribou in all regions 
of the circumpolar Arctic with the exceptions of Svalbard and Iceland (Dieterich et al. 1981; 
Elazhary et al. 1981; Ek-Kommonen 1982; Rehbinder et al. 1992; Hyllseth et al. 1993, Stuen et 
al. 1993, Evans et al. 2012). CvHV2 was first described in Finland in 1980 during a BoHV1 
serology study of semi-domesticated reindeer (Ek-Kommonen et al. 1982). When BoHV1 
antibody neutralization tests showed a seroprevalence of 23% in Finnish reindeer sampled in a 
region with no seropositive cattle, it was hypothesized that a novel alphaherpesvirus was 
circulating in the reindeer population (Ek-Kommonen et al. 1982). Identification of CvHV2 as an 
alphaherpesvirus distinct from BoHV1 was later confirmed when it was isolated in 1986 (Ek-
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Kommonen et al. 1986). Antigenic similarities between alphaherpesviruses, including CvHV2 
and BoHV1, reduce the specificity of some serology tests (Deregt et al. 2005; Lyaku et al. 1992; 
Thiry et al. 2006; Das Neves et al. 2010). ELISA kits most commonly used for identification of 
alphaherpesviruses in ruminants utilize glycoprotein B has the antigen, coded by the mostly 
highly conserved gene in the genome of ruminant alphaherpesviruses (Ross and Belak 2002). 
This means that not all ELISA kits will be able to identify which alphaherpesvirus is present. 
Viral isolation and PCR analysis are more specific alternatives (Ros et al. 1999; Das Neves et al. 
2010), while ELISA tests detect previous exposure to the virus, viral isolation and PCR detect 
active infections with actual presence of viral particles. 
 
Cervid Herpesvirus 2 (CvHV2) is enzootic in reindeer throughout Fennoscandia (Das Neves et 
al. 2009e; Romano et al. 2018; Tryland et al. 2018). A large serological study of 3026 serum 
samples from semi-domesticated reindeer in Finnmark, Norway, found seroprevalence of 
CvHV2 varied from 7.6-90.7% between herding districts, and extrapolated an estimated 
prevalence of 48% among all reindeer in the region (Das Neves et al. 2009e). A study of wild 
reindeer in southern Norway (n=831) showed a seroprevalence of 28.5% (Lillehaug et al. 2003). 
The conditions most highly correlated with CvHV2 seroprevalence are age and animal density 
(Lillehaug et al. 2003; Das Neves et al. 2009).  Das Neves et al. (2009e) also found that 
increased reindeer densities within herding districts are significantly associated with higher 
CvHV2 occurrence, similar to what has been documented in extensive cattle studies of BoHV1 
(Miller 1991; Van Wuijckhuise et al. 1998). Seroprevalence of CvHV2 is highly variable 
between age classes, with markedly higher prevalence among adult animals than calves (Das 
Neves et al. 2009e; Lillehaug et al. 2003; Ek-Kommonen et al. 1982). This reflects the 
characteristic nature of herpesviruses that establish life-long infections with periods of latency 
and reactivation. Adult animals are more likely than calves to have been exposed to CvHV2 and 
become carriers of the virus, further spreading the virus to other individuals. 
 
1.3.3 Transmission and Pathogenesis 
Alphaherpesviruses in ruminants, including CvHV2, are spread by close contact with infected 
animals and contact with contagious aerosols and fomites (Engels and Ackermann 1996; 
Muylkens et al. 2007). CvHV2 infections are known to originate in the mucosa and epithelium of 
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the upper respiratory tract, genital tract, and conjunctiva (Das Neves et al. 2009a; Tryland et al. 
2009; Tryland et al. 2017).  Having gained entry to a host, CvHV2 initiates a lytic infection 
which causes epithelium damage leading to lesions and erosions in the eye, conjunctiva, oral and 
nasal cavities and genital tract (Das Neves et al. 2009a, Tryland et al. 2009, Tryland et al. 2017). 
Movement of viral particles from the initial infection site is poorly understood, but viremia has 
been shown to occur in experimental studies of both primary infections (inoculation) and upon 
reactivation of latent infections (Das Neves et al. 2009a; Das Neves et al. 2009b). CvHV2 was 
detected in a wide variety of tissues including lung, liver, lymph nodes, testicles, mammary 
glands, and spleen (Das Neves et al. 2009a). CvHV2 has also been detected in fetal tissues 
removed from adult females in experimental infection studies, indicating that vertical 
transmission occurs (Das Neves et al. 2009a). Observation of naturally occurring reactivations 
and experimental studies treating seropositive reindeer with the immunosuppressing drug 
dexamethasone confirmed that CvHV2 establishes latent infections as is characteristic of all 
herpesviruses (Rockborn et al. 1990; Das Neves et al. 2009b). CvHV2 has been detected in the 
trigeminal ganglion in experimental studies, suggesting that latency establishes in those nervous 
tissues (Das Neves et al. 2009a).  
 
The impacts of CvHV2 are not well understood due to lack of scientific investigation and 
difficulty observing free-ranging reindeer year-round. . Even though CvHV2 was considered to 
cause asymptomatic infections (Nettleton et al. 1988, Thiry et al. 2006), experimental studies 
have shown that CvHV2 may be associated with abortion and neonatal diseases and it is well 
documented that CvHV2 causes respiratory and genital tract infections, and eye disease of 
varying severity (Rockborn et al. 1990; Das Neves et al. 2009 exp inf; Tryland et al. 2009; 
Tryland et al. 2017).   CvHV2 was described as the causative infectious agent in a 2009 outbreak 
of infectious keratoconjunctivitis (IKC) in Troms County, Norway (Tryland et al. 2009). A 2014 
experimental study further confirmed the connection between CvHV2 and IKC, by documenting 
the development of severe infections in reindeer calves ocularly inoculated with CvHV2 





1.4 Antiviral drugs 
Because of fundamental differences between the nature of bacterial and viral replication, 
antiviral drugs rely on pointedly different mechanisms of inhibition than antibiotics. Viruses are 
not capable of autonomous replication like bacterial binary fission, and instead, must invade host 
cells and utilize cellular mechanics to replicate (Forterre 2006). Therefore, the challenge of 
antiviral drug development is that the compound must be effective in inhibiting viral replication, 
but not cause toxicity by damaging host cells, or minimize the toxic effect compared to the 
antiviral effect (Fields et al. 2001). There are two general classes of antiviral drugs: drugs which 
target the virus directly and drugs which target the host cell in order to inhibit viral replication. 
Antiviral drugs that target cellular mechanisms are more likely to result in greater cell toxicity 
than drugs that target viral mechanisms (Westreenen and Boucher 2002).  
 
One of the largest families of antiviral drugs are nucleoside and nucleotide analogs which 
employ mechanisms of inhibition that cause termination of elongating DNA or RNA strand 
during replication of the viral genome (Clercq and Neyts 2009). Nucleosides are 
unphosphorylated sugar bases of nucleotides, the organic monomers that represents building 
blocks for constructing the double strands of DNA. Nucleoside analogs are molecules that share 
a similar composition and structure to naturally occurring nucleosides and after undergoing 
multiple intracellular phosphorylation steps, can be incorporated into the elongating DNA or 
RNA strand as in place of natural nucleotides during transcription (Clercq and Neyts 2009). 
Nucleotide similarly incorporated into the elongating DNA or RNA strand, but do not require the 
first initial phosphorylation step as nucleoside analogs do (Clercq and Neyts 2009). Once either 
molecule is incorporated into the growing DNA or RNA strand, termination occurs because 
analog does not contain the 3’-hydroxyl function at the (2’-deoxy)riboside moiety, and therefore 
does not have the correct configuration to bind with the subsequently added nucleotide (Clercq 
and Neyts 2009).  
 
No antiviral drug is currently known to be effective in blocking CvHV2 replication. Acyclovir, 
nucleoside analog and common antiherpetic treatment used in humans, is the only drug 
previously tested against CvHV2 (Roche 2016). Acyclovir showed limited inhibition of CvHV2 
when tested in vitro with Madin-Darby bovine kidney cells. This experiment contrasted with 
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other acyclovir studies of closely related ruminant alphaherpesviruses. Acyclovir has been shown 
to successfully block BoHV1 in vitro infections, and in combination with the imidazole 
nucleoside Mizoribine, acyclovir was found to be effective against CpHV1 (Collins 1983; Enan 
et al. 2012; Elia et al. 2015; Camero et al. 2017). Ganciclovir, an acyclovir homologue, is known 
to inhibit equine herpesvirus 1 and 3 (Smith et al. 1983; Enan et al. 2012). Outside of in vitro 
studies, CpHV1 infections have been successfully treated with cidofovir, a cytidine nucleoside 
analogue (Tempestra et al. 2007; Tempestra et al. 2008). Based on their documented 
effectiveness of other ruminant alphaherpesvirus inhibition in previous studies, ganciclovir and 
cidofovir were chosen to be tested against CvHV2 in this project. 
 
1.4.1 Ganciclovir 
Developed in the 1982, ganciclovir (Cymevene, Cytovene; Fig. 5) is a guanosine nucleoside 
analogue that has primarily been used in human medicine to treat cytomegalovirus diseases in 
AIDS patients (Ovilvie et al. 1982; Pape 1988; Jabs et al. 1989, Clercq and Neyts 2009). Oral 
bioavailability of ganciclovir is <10% and the drug is typically administered in humans by 
intravenous injection (Kimberlin and Whitley 2007). Antiherpetic ability of ganciclovir has been 
demonstrated and is highly effective in treating HSV-1 and HSV-2, though it is rarely used for 
this purpose due to concerns of carcinogenicity and reproductive toxicity (Jacbonson et al. 1987). 
 




The mechanism of inhibition of ganciclovir (Fig. 6) blocks viral replication by inhibiting viral 
DNA polymerases as it competitively blocks incorporation of guanosine nucleotides and by 
terminating DNA chain elongation (Crumpacker at el. 1979; Chen et al. 2014). Ganciclovir 
converted to ganciclovir triphosphate in the cell’s cytoplasm, phosphorylated once by viral 
thymidine kinase (TK) and twice by cellular enzymes, before it is incorporated into the DNA 
strand (Martin et al. 1983). Ganciclovir contains an equivalent structure of a 3’-hydroxyl group 
that allows nucleotides to be added to the DNA strand in some viral species, but when treating 
herpesviruses, the molecule does not have the correct conformation to bind to an incoming 
nucleotide  (Markham and Faulds 1994; Clercq and Neyts 2009; Chen et al. 2014). 
 
Figure 6. Ganciclovir’s mechanism of inhibition of HSV-1, including the tri-phosphorylation, 
once by viral TK (2) and twice by cellular enzymes (3/4), and incorporation into the DNA strand 
(5) leading to termination of strand elongation (6). Adapted with permission from Clercq and 
Neyts 2009. 
HO HO HO 






Cidofovir (Vistide; Figure 7) is a monophosphate acyclic nucleotide analog, specifically an 
acyclic cytosine analogue, with a broad spectrum of antiviral activity, known to be effective 
against herpesviruses, adenoviruses and papillomaviruses (De Clercq et al. 1986). In the same 
nucleoside family of antiviral drugs as ganciclovir, cidofovir is a cytosine nucleoside analogue 
rather than a guanosine nucleoside analog like ganciclovir. Cidofovir is a highly important 
treatment for CMV retinitis in human AIDS patients (Kirsch et al. 1995). During initial animal 
testing when cidofovir was being developed, it was found that the drug was successful in treating 
HSV1 infections in mice and rabbits, including localized therapy of herpetic keratitis (De Clercq 
et al. 1986). Cidofovir tested in veterinary in vivo studies have also shown success of topically 
applied cidofovir cream solutions against CpHV1 and canine herpesvirus-1 (CHV1) (Tempesta 
et al. 2008; Ledbetter et al. 2015).  
  
Figure 7.  Chemical structure of Cidofovir, with the monophosphate group highlighted in a blue 
circle. Adapted with permission from Clercq and Neyts 2009. 
 
The structure of cidofovir molecules causes relatively poor uptake into infected cells as its 
negatively charged configuration slows its entry endocytosis (Connelly et al. 1993). The 
monophosphate group slows cellular uptake as the negatively charged moiety is repelled by the 
similarly negatively charged heads of the phospholipid bilayer of the cell. However, despite poor 
uptake of the drug, once the drug has entered the cell, the phosphorylated forms of cidofovir 
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have relatively long half-lives (17-65 hours in humans) and allows for prolonged antiviral 
activity (Ho et al. 1992; Aduma et al. 1995).  
 
The mechanism of inhibition of cidofovir (Figure 8) is similar to that of ganciclovir, but 
cidofovir is a phosphonate, requiring only two phosphorylation steps to act as a substrate for 
viral DNA polymerase and the phosphorylation is completely only by cellular enzymes and not 
viral TK (Ho et al. 1992; Aduma et al. 1995). As cidofovir is incorporated into the growing DNA 
chain of replicating viral particles, transcription drastically slows down and when two successive 
cidofovir molecules have been added to the strand, transcription stops (Xiong et al. 1997).  
 
 
Figure 8. Cidofovir’s mechanism of inhibition of HSV-1, including the two step phosphorylation 
from the monophosphate form (1) by cellular enzymes (2/3) and incorporation into the DNA 
strand (4) leading to termination of strand elongation (5). Adapted with permission from Clercq 
and Neyts 2009. 





1.4 Aim of Study 
 
The purpose of this study was to investigate the antiviral effect of Ganciclovir and Cidofovir 
against CvHV2 in a preliminary in vitro model with MDBK cells, and to evaluate their potential 




1. Is there a dose-dependent relationship between Ganciclovir or Cidofovir and estimated 
CvHV2 titers after 72 hours exposure to the drugs? 
 
2. If yes, what is the strength of that relationship? Could Ganciclovir or Cidofovir be considered 
for further studies and possible use as a treatment for IKC in semi-domesticated reindeer?
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2. Materials and methods 
 
2.1 MDBK-cells: culture conditions and maintenance 
A culture of a continuous cell line of MDBK cells (American Type Culture Collection, CCL-
22TM; Fig. 9). The cells were grown in 75cm2 or 150cm2 plastic cell culture flasks 
(ThermoFisher, Waltham, USA) with Eagle’s minimum essential medium (EMEM) (Sigma-
Aldrich, St. Louis, USA) supplemented with 10% horse serum (Sigma-Aldrich, St. Louis, USA) 
and incubated at 37.5C with 5% CO2. The cells were subcultured when cell density reached 70-
80%,typically after 2-3 days (See Appendix 1). Viability of the culture was confirmed 
throughout the experiment by use of 0.4% Trypan Blue (Sigma-Aldrich, St. Louis, USA) when 
counting cells during subculturing and by regular observation under a microscope. Trypan Blue 
is only absorbed by living cells, so it can be used as a dye exclusion test for viability (Strober 
2013).  
 
Figure 9. MDBK at medium density (<50% confluence) and actively replicating. Dividing cells 






2.2 Cytotoxicity assay 
A cytotoxicity assay was used to determine the maximum concentration of each drug that could 
be used in MDBK cell culture.  The assay was completed using a MTT Cell proliferation Kit I 
(Roche Life Science, Mannheim, Germany) following the manufacturer’s protocol. The MTT 
Test Kit assessed metabolic activity by measuring the conversion of the yellow tetrazolium salt 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) to purple formazan 
crystals ((E,Z)-5-[4,5-dimethylthiazol-2-yl]-1,3-diphenylformazan) in the mitochondria of cells. 
This assay assumes normal metabolic function measured by the MTT Test Kit is an indicator of 
cells experiencing no significant cytotoxic effect from the antiviral drug and can be used as a 
measure of viability (Van Meerloo et al. 2011). 
 
MDBK cells were seeded into three 96-well cell culture plates (FalconTM, BD Biosciences, 
Franklin Lakes, USA) at a density of 2.5 x 104 cells per well, incubated for 24-hours, and then 
exposed to a panel of concentrations of each antiviral drug. Ganciclovir concentrations of  
1600 μM, 1200 μM, 800 μM, 600 μM, 400 μM, 200 μM, 100 μM, 50 μM, 25 μM, and 12.5 μM 
and Cidofovir concentrations of 300 μM, 200 μM, 150 μM, 100 μM, 75 μM, 50 μM, 25 μM,  
12,5 μM, 6,25 μM, and 5 μM were tested. Both a negative control (no antiviral drug, + MTT) 
and a background (no antiviral drug, no MTT) were used on each plate (Fig. 10). 
 
Figure 10. 96-well plate in the MTT cytotoxicity assay. The two controls are highlighted with a 




After the plates were incubated for 72-hours, mimicking the experimental conditions of the later 
antiviral assay, the MTT solution was added and incubated to allow the conversion of the yellow 
tetrazolium salt to purple formazan crystals to occur. The solubilizing solution was then added to 
dissolve any crystals present and the plates were incubated for an additional 24-hours. The 
amount of purple formazan crystals present was quantified by measuring the absorbance (as 
optical density) of the solutions with a microplate reader (Epoch Microplate Spectrophotometer, 
BioTek, Winooski, USA) at a wavelength of 650nm. The negative control was used for reference 
for the absorbance values. The resulting absorbance values were used to calculate the percentage 
of cytotoxicity . 
 
% 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =  
𝑂𝐷𝑐 − 𝑂𝐷𝑡
𝑂𝐷𝑐
 𝑥 100% 
 
  ODc= Optical density of the control, ODt= Optical density of the test. 
 
Equation 1: Calculation of percentage of cytotoxicity.  
2.3 Antiviral Assay 
The antiviral assay was composed of two different tests to measure the inhibitory ability of the 
antiviral drugs: an experimental CvHV2 infection of MDBK cells, and a 50% Tissue Culture 
Infectious Dose (TCID50) assay to quantify the lowest infectious titer of the virus which caused 
CPE. Frozen stock of 4.22 x 105 TCID50/mL CvHV2 originally isolated from reindeer affected 
by IKC in Troms County, 2009, was used for the experimental infection (Tryland et al. 2009). 
 
2.3.1 Experimental infection and antiviral challenge 
A solution of MDBK cells in EMEM and horse serum (10%) was distributed into 24-well plates 
(NuncTM, ThermoFisher Scientific, Waltham, USA) at a density of 1.5 x 105 cells per well and 
incubated (37C, 5% CO2) for 24 hours to achieve a cell monolayer in each well. Each plate was 
subsequently inoculated with a single concentration of antiviral drug to be tested (one plate for 
each concentration), followed by six tenfold dilutions of CvHV2 (105, 104, 103, 102, 101, and 100 
TCID50/mL). Each combination of drug concentration and viral dilution (example: 200 M 
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Ganciclovir and 104 TDCID50/mL CvHV2) had three replicate wells included on the same 24-
well plate. The maximum drug concentrations tested in the antiviral assay were selected based on 
the results of the cytotoxicity assays. Both a positive (antiviral drug without CvHV2) and 
negative (only MDBK cells, without antiviral drug or CvHV2) controls were used. While a 
control plate (MDBK cells, without antiviral drug) was also inoculated with the CvHV2 dilutions 
as the viral control. 
 
The 24-well plates were incubated for three days (37C, 5% CO2) and observed with a 
microscope. Any visible CPE was documented and photographed (Fig. 11). In order to fully lyse 
the MDBK cells and release intracellular viral particles, the 24-well plates were subjected to 
three freeze-thaw cycles at -80C. The supernatant and cell debris were collected in Eppendorf 
tubes and frozen at -80C until later use in the TCID50 assay. The solutions from the three 
replicate wells for each combination of drug concentration and viral dilution were pooled into the 
same Eppendorf tube. 
                                    (A)                                                                             (B) 
 
  
Figure 11. MDBK cell monolayer during the experimental infection and antiviral challenge, 








2.3.2 TCID50 Viral Quantification Assay 
The TCID50 assay performed in this experiment is an endpoint dilution assay that quantifies the 
amount of viable virus after exposure to Ganciclovir and Cidofovir. Using the solutions collected 
during the antiviral challenge experiments, a 10-fold dilution series (10-1 to 10-8) was performed 
for each drug concentration and viral dilution and pipetted into 96-well plates containing 25,000 
MDBK cells per well. The plates were incubated (37C, 5% CO2) for three days to allow any 
subsequent CPE to become visible. After the incubation period, the cells were fixed using 100 
μL formaldehyde (3.7%) per well, dyed with 50 μL Crystal Violet solution (0.1%), and observed 
visually for the presence of CPE. 
 
The TCID50 values were calculated using the Reed-Muench counting method (Reed and Muench 
1938; Hierholzer and Killington 2005). This method involves counting rows of the 96-well plate 
that have visible CPE and calculating the 50% dilution endpoint. The TCID50 value will be 
between the last row of dilutions in which >50% of the wells show CPE and the first row 
showing <50% CPE and is a method to quantify the remaining number of viable viral particles 
after exposure to the antiviral. 
 
2.3.3 Statistics and Analysis 
Statistical analysis was completed using R software (Version 0.99.878, 2009-2016). Simple 
Linear Models were used to analysis the results of the antiviral assay. Results of the Linear 
Model analysis were considered significant with p-values < 0.05. Descriptive statistics in the 










3.1 Cytotoxicity assay 
Cell viability was evaluated after 72-hour exposure (37C and 5% CO2) to ganciclovir and 
cidofovir, in two respective runs of the MTT cytotoxicity assay. Ganciclovir caused a marked 
drop in cell viability at concentrations >200 μM, reducing cell viability by 20% or greater (Fig. 
12). Cell viability dropped to less than 50% for concentrations above 600 μM ganciclovir. 
Concentrations below the cytotoxicity concentration 20 threshold (CC20), meaning the 
concentrations that did not cause reduce cell viability by more than 20%, were accepted as 
candidate ganciclovir concentrations for use in the sequent antiviral assay. 
 
 
Figure 12.  Ganciclovir MTT cytotoxicity assay results: average percentage of viable cultured 
MDBK cells after 72-hour exposure to a panel of ganciclovir concentrations (n=24 per 





























No cidofovir concentration tested in the MTT cytotoxicity assay caused a reduction of cell 
viability greater than 31% (Fig. 13). Cells exposed to cidofovir concentrations 75M, 100 M, 
150 M, 200 M and 300 M were <80% viable, thus concentrations 50 M were below the 
CC20 threshold and were considered for use in the later antiviral assay. 
 
 
Figure 13. Cidofovir MTT cytotoxicity assay results: average percentage of viable cultured 
MDBK cells after 72-hour exposure to a panel of Cidofovir concentrations (n=24 per 
concentration). The CC20 threshold is marked by a dashed line at 80% cell viability. 
 
 
3.2 Antiviral Assay 
Viral titers after 72-hour exposure to ganciclovir and cidofovir were estimated with the Reed-
Muench counting method (Reed and Muench 1938) and calculation of TCID50 values (Equation 
2). The TCID50 viral titers decreased with increasing drug concentrations for both ganciclovir 



























ganciclovir and 3.125 cidofovir (Table 2). At these lowest concentrations, titers were seemingly 
comparable to the titers of the untreated wells. The greatest reduction in viral titers occurred with 
the 100 initial viral load with the highest antiviral concentrations, 200 μM ganciclovir and 50 μM 
cidofovir. This combination of the 100 initial viral load and the highest antiviral concentrations 
resulted in first degree titers levels of 1.20 and 1.87 log10 TCID50/mL, for ganciclovir and 
cidofovir respectively. Reduction in titers with initial viral loads 102-105 TCID50/mL ranged 
from 2.32 to 3.50 log10 TCID50/mL with 200 μM ganciclovir and 2.21 to 3.75 log10 TCID50/mL 
with cidofovir. Complete inhibition of  CvHV2 replication did not occur with any combination 
of initial viral load and antiviral drug concentration tested. 
 
Table 1. Antiviral activity of ganciclovir (GCV) and cidofovir (CID) shown through TCID50/mL 
values across a panel of initial viral inoculation loads (100-105 TCID50/mL) and antiviral 
concentrations. All values are expressed as an average of the two experimental runs with 
TCID50/mL units. 
 
Initial viral   GCV Concentration         
load 
(TCID50/mL)        
    200 μM 50 μM 25 μM 12,5 μM 6,25 μM No GCV 
 
105   104.40 105.24 106.04 106.62 107.28 107.25 
104  10
4.21 105.22 105.72 106.01 106.28 106.53 
103  10
3.71 105.21 106.04 106.26 105.43 106.54 
102  10
3.55 105.05 105.21 104.82 105.71 106.22 
101  10
2.21 104.71 105.23 105.71 106.04 105.71 
100   101.20 103.26 105.20 103.41 105.24 105.21 
 
Initial viral   CID Concentration         
load 
(TCID50/ml)        
    50 μM 25 μM 12,5 μM 6,25 μM 3,125 μM No CID 
 
105   104.87 105.32 105.48 106.93 107.37 107.70 
104  10
5.24 104.59 105.21 106.20 107.20 107.47 
103  10
4.54 105.24 106.21 107.19 107.47 107.47 
102  10
3.95 104.41 105.24 106.93 107.70 107.70 
101  10
3.99 104.31 104.74 106.20 107.70 106.20 
100   101.87 103.00 104.37 105.37 107.70 106.39 
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The strength of the relationship between ganciclovir and cidofovir exposure and viral titers 
estimated by the TCID50 values, was tested with simple linear regression analysis. TCID50/mL 
values were logarithmically transformed prior to the regression analysis and passed standard 
normality and linear model assumption testing. 
 
 A significant (p-value <0.05) negative relationship was found with ganciclovir and all initial 
viral loads, and cidofovir with 105 and 103-101 TCID50/mL initial viral loads, demonstrating a 
negative dose-response of CvHV2 to both drugs. The 104 initial viral load in the cidofovir 
experiment was not shown to be significant (p-value >0.05). 
 
Table 2. Linear regression model results of relationship between ganciclovir (GCV) and 
cidofovir (CID) exposure  and estimated viral titers (TCID50/mL). 
 
Initial 
Viral Load GCV       CID     
 p-value R
2 m (slope)   p-value R2 m (slope) 
105 0.02292 0.7042 -0.013209 
 
0.02746 0.6776 -0.055 
104 0.004864 0.8604 -0.010451 
 
0.1224 0.3604 -0.04345 
103 0.008938 0.8121 -0.012379 
 
0.003394 0.883 -0.06541 
102 0.01747 0.7403 -0.010637 
 
0.01872 0.7315 -0.07436 
101 0.0001396 0.976 -0.018373 
 
0.01278 0.7766 -0.08359 





The percentage of inhibition of CvHV2 by both antiviral drugs was calculated and plotted for 






Figure 14. Inhibition of CvHV2 replication shown as a percentage reduction in TCID50 values in 
cells exposed to antiviral compounds (A: ganciclovir, B: cidofovir) compared to the TCID50 
















































































No veterinary treatment currently exists for management of CvHV2 infections and the only prior 
study investigating the effect of antiviral drugs against CvHV2, found that the commonly used 
antiherpetic drug acyclovir, had limited inhibitory effect (Roche 2016). Due to the indications 
that CvHV2 is the causative agent for IKC in reindeer in Norway (Tryland et al. 2009; Tryland et 
al. 2017), this experiment was designed to provide further insight into future possibilities of 
developing an antiviral treatment for CvHV2, by evaluating the effect of two antiviral drugs, 
ganciclovir and cidofovir, in vitro. 
 
4.1 Cytotoxicity in MDBK cell culture 
Prior to the antiviral assay, it was necessary to establish the maximum concentrations of the two 
antiviral drugs in MDBK cell culture to keep the later antiviral assay unbiased from drug related 
toxicity. In this experiment, drug concentrations were selected for use in the antiviral assay if the 
concentration caused no more than a 20% reduction in cell viability and were above the 
cytotoxic concentration 20 (CC20). It would have been possible to use a stricter selection criteria 
than CC20 because some cytotoxic effect is still occurring at this threshold, however CC20 was 
chosen as it has been previous used as a standard in other similar antiviral drug studies (Elia et 
al. 2015, Roche 2016, Camero et al. 2017). Furthermore, testing of antiviral drugs in vitro using 
an immortal cell line is the most preliminary step in developing a disease treatment and in this 
study it was considered tolerable to accept concentrations at the CC20 threshold in order to test a 
wider panel of drug concentrations and gain as much insight as possible into the effect of the 
drugs.  
 
Because CC20 was used to select the drug concentrations tested, it is possible there may have 
been some bias of drug related toxicity in the concentrations of 200 μM, 50 μM, and 25 μM 
ganciclovir and 50 μM, 25 μM, and 12.5 μM cidofovir. In the context of use in veterinary 
medicine, it would likely be necessary to further consider the impacts of these high 
concentrations to try to minimize potential adverse effects due to toxicity in vivo. In humans, 
ganciclovir is linked to significant myelosuppression leading to anemia and neutropenia in and is 
of carcinogenic concern  (Kimberlin and Whitley 2007, Markham and Faulds 1994). Human 
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HSV keratitis patients topically treated with 0.15% ganciclovir experienced only local effects, 
including superficial punctate keratopathy and conjunctival hyperemia, but both were considered 
highly tolerable by medical observers (Chou and Hong 2014). Systemic adverse effects are 
infrequent with cidofovir, but local effects of topical eye treatments such as inflammation of 
conjunctiva and upper eyelid, are in both humans and animals (Hillenkamp et al. 2002; 
Broekema and Dikkers 2008; Fontenelle et al. 2008).  
 
However, in the context of this preliminary in vitro study, 200 μM, 50 μM, and 25 μM 
ganciclovir and 50 μM, 25 μM, and 12.5 μM cidofovir were considered acceptable to be included 
in the analysis. The TCID50 results of these highest concentrations passed normality and variance 
testing prior to the linear model analysis and were not considered outliers.  
 
4.2 Antiviral effect against CvHV2 
In both the ganciclovir and cidofovir experiments, a statistically significant (p-value <0.05) 
negative relationship was found in the linear model analysis of drug exposure and resulting viral 
titer levels, with the initial viral loads of 100-105 TCID50/mL for ganciclovir and 10
0-103 and 105 
TCID50/mL for cidofovir. This confirms a negative dose-response relationship between both 
drugs and CvHV2 titers. However, it appears that the magnitude of antiviral effect is minimal 
despite the statistically significant dose-response relationship. The resulting slope values range 
from -0.010451 to -0.018777 log(TCID50/mL)/M for ganciclovir and -0.04345 to -0.103354 
log(TCID50/mL)/M for Cidofovir. There was no apparent biological explanation for the one 
single initial viral load was not found to be significant (p-value>0.05), 104 TCID50/mL in the 
cidofovir experiment. This may have occurred because the extremely low slope values of the 
linear regression analysis (-0.04345 log(TCID50/mL)/M). Small natural variation in the 
experiment could have overcome the very low magnitude of effect indicated by the slope values 
and caused the 104 TCID50/mL to not be significant. 
 
Both ganciclovir and cidofovir showed increases trends in the percentage of inhibition with 
increasing drug concentration (Fig.14). Both drugs also exhibited a clear trend of increasing 
CvHV2 inhibition at lower initial viral loads. Overall viral inhibition was low, with only the 
lowest initial viral loads, 101 and 100 TCID50/mL with the highest concentrations of ganciclovir 
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and cidofovir causing more than 50% inhibition. Calculation of half maximal inhibitory 
concentration (IC50) was not calculated in this experiment because 50% inhibition did not occur 
with such a majority of the initial viral loads. 
 
Based on the linear model results, ganciclovir and cidofovir were more successful in inhibiting 
CvHV2 than acyclovir, the only other antiviral drug previously tested against CvHV2 (Roche 
2016). In the acyclovir study, linear modeling was also used to analysis the strength of the 
relationship between drug exposure and estimated viral titers and a significant negative dose-
response relationship was only found at initial viral loads of 101 and 102 TCID50/ml. In this study 
of ganciclovir and cidofovir, a significant dose-response relationship was found at initial viral 
loads of 100-105 TCID50/ml for ganciclovir and 10
0-103 and 105 TCID50/ml for cidofovir. The 
maximum reduction of estimated CvHV2 titers by acyclovir was 1.67 log10 TCID500/ml while 
the maximum reductions caused by ganciclovir and cidofovir were 3.5 log10 TCID50/ml and 3.75 
log10 TCID50/ml respectively.  
 
Comparison of ganciclovir or cidofovir to the results of other antiviral drug tests can be made by 
contrasting viral inhibition values or TCID50 results directly. The viral inhibition caused by 
ganciclovir and cidofovir appears only moderate compared to previous studies of other 
nucleoside analog antiviral drugs considered successful in treating related alphaherpesvirus. No 
combination of initial viral load and ganciclovir or cidofovir concentration resulted in complete 
inhibition of CvHV2. A feline herpesvirus 1 (FHV1) in vitro study of a panel of antiviral drugs 
including ganciclovir and cidofovir, found that both drugs were much more powerful inhibitors 
of FHV1 at similar concentrations to those tested in this study (van der Meulen et al. 2006). 
Using a plaque-reduction assay instead of estimating viral titers through TCID50 calculations, 
van der Meulen et al. found <75% reduction in plaque number at a ganciclovir concentration of 
27 μM and a cidofovir concentration of 32 μM. CvHV2 was inhibited <40% at similar 
concentrations of ganciclovir and cidofovir respectively. A paired in vitro and in vivo of canine 
herpesvirus 1 (CHV1) found cidofovir to highly successful in inhibiting CHV1 in MDBK cell 
culture, with a half maximal effective concentration (EC50) of 4.4 ± 2.3 μM and over 75% 
inhibition occuring with 50 μM (Ledbetter et al. 2015).  The lowest concentration of cidofovir 
tested with CvHV2 was 3.125 μM and caused <10% inhibition of viral activity.  
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Given the seemingly moderate the antiviral effects of ganciclovir and cidofovir against CvHV2 
to other successful studies of related herpesviruses, ganciclovir and cidofovir may be candidates 
for development as treatments for IKC infections in reindeer only with certain considerations.  
 
While it could be possible to simply test concentrations of ganciclovir and cidofovir to try to  
achieve greater inhibition of CvHV2, this would cause too much cytotoxicity. An already lenient 
cytotoxicity threshold (CC20) was chosen for this study order to test a wider panel of drug 
concentrations in this preliminary stage of treatment testing, and complete inhibition of CvHV2 
did not occur even at the highest concentrations tested. Ideal candidate drugs for development as 
a treatment in vivo are have a high therapeutic index, meaning they are highly effective with low 
toxicity, (Prusoff et al. 1989). Therefore, possibilities to further increase the effect of either drug 
should be considered, such that complete inhibition of CvHV2 would occur with treatment of 
fully non-toxic concentrations.  
 
A synergistic antiviral effect of the immunosuppressive drug mizoribine has been found with 
guanosine nucleoside analogs which could potentially increase the effect of ganciclovir against 
CvHV2. In treatment of CpHV1, acyclovir alone, in concentrations up to 440 μM, were not 
successful in significantly reducing viral replication, but with the addition of 154 μM mizoribine, 
a concentration of 28.5 μM acyclovir was successful in reducing CpHV1 activity by 50% and 
440 μM caused complete inhibition of the viral replication (Elia et al. 2015). There are no 
previous studies of ganciclovir and mizoribine in the treatment of alphaherpesviruses, but the 
combination has been shown to have a strong synergistic effect in inhibiting cytomegalovirus, a 
betaherpesvirus, replication in vitro (Kuramoto et al. 2010). 
 
As there are no known synergistic combinations of cidofovir with other compounds, it may not 
be possible to increase the therapeutic index of cidofovir in treating CvHV2, but given the 
success of in vivo cidofovir treatment against other herpesvirus infections, this may be could be 
considered acceptable. A intravaginal cidofovir treatment in goats experimentally inoculated 
with CpHV1, was able to prevent development of genital lesions and reduced viral shedding in 
effected animals (Tempesta et al. 2008). Topical cidofovir solutions have also been found to be 
successful in the treatment of herpetic eye diseases in domestic dogs and cats, but are associated 
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with moderate local ocular toxicity effects such as exacerbation of conjunctivitis and ulcerative 
blepharitis in both species (Fontenelle et al. 2008; Ledbetter et al. 2015).  
 
4.3 Development of a practical treatment 
After considering methods to increase the therapeutic index of either ganciclovir or cidofovir, the 
next steps in developing an antiviral treatment for IKC would include a secondary in vitro study 
in primary reindeer cells, specifically either corneal or conjunctival epithelial cells. Using an 
immortal cell line such as MDBK is very useful in a preliminary because they are commercially 
produced and can be easily maintained in a lab setting (Prusoff et al. 1989). However, using a 
species specific cell type would better address the behavior of CvHV2 in reindeer, its natural 
host. Developing primary reindeer cell lines would be challenging as no established protocol for 
reindeer corneal or conjunctival cells exists, but protocols for establishment of similar primary 
cell lines from humans, dogs, and cats are published and may be a useful starting point (Kim et 
al. 2004; Sandmeyer et al. 2005; Werner et al. 2007). 
 
The final and most relevant step in developing an antiviral treatment for CvHV2 would be 
testing the drug as a treatment in live, either in under experimental conditions or through off-
label use during a naturally occuring outbreak of IKC. Testing off-label during an outbreak 
would be a highly convenient to test the treatments as it would require far less costs and planning 
as a controlled, inoculation study, but this would be less scientifically and statistically rigorous 
than an experimental inoculation study design (Gazarian et al. 2006). An experimental treatment 
study would allow for most conditions of the infection to be controlled including timing of the 
inoculation, observation before and after application of the treatment, and even simply 
standardization of the initial pathogen. While CvHV2 has been clearly shown to be a causative 
agent of IKC in Norway, IKC is a multifactorial disease and there are other viruses and bacteria 
associated with the condition (Tryland et al. 2009; Tryland et al. 2017). It is not possible to know 
in the field during an outbreak if additional pathogens are contributing to the disease (Tryland et 
al. 2009; Tryland et al. 2017).  
 
Even with the development of a successful antiviral treatment for IKC, there will be significant 
challenges in animals that are free-ranging most of the year and experience increased stress when 
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handled (Wiklund et al. 1995). The most useful treatment of IKC in reindeer would involve a 
minimal number of applications, preferably one single administration of the drug. Systemic 
treatment of IKC would likely be more practical than a topical treatment as it could be delivered 
in a single dose and alleviate the need for affected animals to be corralled and handled multiple 
times per day for application of the topical drug solution. Cidofovir may be a better candidate for 
development of a systemic treatment than ganciclovir, given the adverse effects associated with 
systemic ganciclovir treatment (Jacbonson et al. 1987), as well as the long half-life and extended 
intracellular retention of cidofovir (Ho et al. 1992; Markham and Faulds 1994; Aduma et al. 
1995; Kimberlin and Whitley 2007). A rabbit model study of human CMV retinitis, showed that 
cidofovir is exceptional well retained in the vitreous humor and continued to exhibit an 
antiherpetic effect up to ten days following a three day treatment (Flores-Aguilar et al. 1994). 
Extended intracellular ocular retention of cidofovir could be an ideal quality for a one-time 




This study investigated the antiviral effects of ganciclovir and cidofovir against CvHV2 in vitro, 
with the aim of identifying a candidate drug for development of a treatment for IKC in semi-
domesticated reindeer. A significant dose-dependent relationship between exposure to 
ganciclovir and cidofovir and estimated viral titer levels, however, neither drug caused complete 
inhibition of CvHV2  and only a moderate percent of CvHV2 inhibition occurred. This indicated 
that ganciclovir and cidofovir are candidates for further study of candidate drugs for 
development of a treatment for IKC, only if possibilities to increase the therapeutic index of 
either ganciclovir or cidofovir is considered. Development of a practical antiviral treatment for 
IKC in free-ranging semi-domesticated reindeer will be challenging, but would, based on the 
enzootic distribution of CvHV2 in many reindeer populations and its ability to cause IKC, be a 
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Appendix 1: Maintenance of MDBK Cell Culture 
 
 
DESCRIPTION: Establishment and care of Madin-Darby bovine kidney (MDBK) cell line 




Plastic cell culture bottles (T25 and T75 or T150) 
Eagle’s Minimal Essential Medium (EMEM) supplemented with: 
Horse serum (HS) 10%. 
50 mL Falcon tubes  
1.5 mL Eppendorf tubes 
Trypan blue 
Counting chamber 
Pipettes, pipette-boy, tips 
PBS (phosphate buffered saline) 
Trypsin solution 
 
ESTABLISHING A NEW CULTURE: 
 
1. Pre-heat a small volume (20 mL) of water to 37 °C. 
2. Remove cryovial of MDBK cells from liquid nitrogen storage. 
3. Suspend cryovial in pre-heated water bath and place inside a 37 °C incubator. 
4. Pre-heat medium (EMEM with 10% HS) 
 
All work with the cells must be done inside a laminar flow cabinet, wearing protective gloves 
and coat to prevent contamination of the cell culture.  
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5. Once cell suspension is thawed, remove cryovial from water bath and wipe outside of vial with 
alcohol solution to evaporate any remaining water. 
6. Transfer the content of cryovial to a T25 bottle with 5 mL of preheated medium. 
7. Incubate at 37 °C with 5% CO2 for 24 hours  
8. Remove medium and replace with fresh, pre-warmed EMEM + 10% HS 
 
MAINTENCE AFTER ESTABLISHMENT: 
 
Incubate the established culture at 37°C with 5% CO2 until cell density requires subculturing. 
The density and morphology of the cells can be controlled by observing the culture in a 
microscope. The cells should be subcultured when the cells have reached a confluence of 
approximately 70-80% within the cell culture bottle. Subculturing typically is required every 3-4 
days. If the cells are growing at a slower rate, such that subculturing is not required after 4 days, 




1. Remove medium from the culture bottle using an aspirator 
2. Gently wash cell layer with 10 mL PBS  
3. Remove PBS from culture bottle with aspirator 
3. Add 4mL Trypsin (For T150 bottle. Use more or less depending on bottle volume) 
4. Incubate at 37 °C for 2 – 5 minutes 
5. Collect cells by gently tapping culture bottle against a solid surface (to fully detach all cells 
after Trypsin exposure)  
6. Transfer the content of the bottle to a 50 mL Falcon tube (with a pipette-boy) 
7. Centrifuge tube at 1200 rpm for 5 minutes 
8. Observe that the cells have formed a pellet in the bottom of the tube  
9. Remove supernatant with aspirator, leaving pellet of cells intact 
10. Resuspend pellet with 2 mL EMEM  
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11. Count the cell density to determine volume of cell solution to be transferred to the new 
culture bottle: 
a. Pipette 180 µL Trypan blue to an Eppendorf-tube 
b. Transfer 20 µL of the cell suspension to the tube with Trypan blue and mix 
thoroughly (1:10 dilution) 
c. Transfer 20 µL of colored cell suspension to counting chamber  
d. Count cells at magnification 10x in the microscope 
e. Count cells inside the central 0.1mm2 square (show above in red). The cells on the 
right bottom border are counted as inside, while the cells on the top and left 
borders are not count.  
 
12. After counting, prepare a new bottle to be inoculated  (5 mL EMEM + HS for a T25 bottle, 
12 mL EMEM + HS for a T75 bottle or 30 mL EMEM + HS for a T150 bottle) 
Calculation of counted cells 
Every small square in the middle has an area of 0,004 mm2 
25 squares with the volume of 25 x 0.004 = 0,1 mm2 
 
If 30 cells are counted in a volume of 0,1 mm2 – that means 30/0.1 = 300 cells/mm2 
There are 1000 mm2 in one cm2 (same as 1 mL) 
The particle count in the trypan blue solution is 300 x 1000 = 300 000 cells/mL 
The trypan blue solution is a 1:10 dilution of original suspension – 300 000 x 10 = 3 000 000 cells/ml 
 
Dividing x (counted number of cells pr. 25 squares) by 0.1 and multiplying by 1000 and 10 will be the 
same as multiplying x by 100 000 
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13. Determine the volume to transfer to the new bottles to obtain the desired density of the cells. 
MDBK cells should be seeded out at 250,000 cells/T25 bottle, 750,000 cells/T75 bottle or 
3,000,000 cells/T150 bottle. 
Transfer volume to be calculated as:   
 
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑖𝑛 𝑛𝑒𝑤 𝑏𝑜𝑡𝑡𝑙𝑒
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑠 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛
= 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑏𝑒 𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑟𝑟𝑒𝑑 (𝑖𝑛 𝑚𝐿) 
 
14. Transfer appropriate volume to the new bottle(s) and carefully tip bottle a couple of times to 
make sure the cells are evenly distributed to avoid clumping as the cells attach to the bottle 




Appendix 2: MTT Cytotoxicity Assay 




MTT Cell Proliferation Kit I (Sigma Aldrich, St. Louis, USA) 
96-well plates (Nunc Edge 2.0, ThermoFisher Scientific, Waltham, USA) 
MDBK cells 
Antiviral drug solution 
Eagle’s Minimal Essential Medium (EMEM) supplemented with 10% HS 
Pipettes, filtered tips 





1. Subculture MDBK cells and count cell density (as described in Maintenance of MDBK Cells) 
 2. Plate 25,000 cells/well into three 96-well plates. Use 100 uL EMEM + 10% HS for each well 
aliquot. 
3. Incubate plates for 24 hours at 37°C with 5% CO2 
4. After 24 hours, prepare the concentrations of antiviral drug to be tested and incubate to 37°C 
5. Remove medium from 96-well plates by turning upside down and gently tapping over waste 
container. 
6. Add 100 uL of antiviral solution in each well for columns 3-12 (treatment columns) 
7. Add 100 uL of EMEM + 2% HS in each well for columns 1-2 (controls columns) 
8. Incubate for 72 hours at 37°C and 5% CO2 
a. Check cells every 24 hours for adherence and proper growth 
9. Add 10 uL MTT Salt (from Cell Proliferation Kit 1) to wells, skipping column 2 in each plate 
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10. Incubate for 4 hours at 37°C and 5% CO2 
11. Add 100 uL MTT Buffer to all wells 
12. Measure absorbances on ELISA plate reader (wavelength 570 nm) 
13. Calculate cell viability with the following formula: 
 
% 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =  
𝑂𝐷𝑐 − 𝑂𝐷𝑡
𝑂𝐷𝑐
 𝑥 100% 
 









Appendix 3: Experimental CvHV-2 Infection 
 
DESCRIPTION: Experimental infection of MDBK cell culture with CvHV2 as in vitro 




24-well plates (Nunc Edge 2.0, ThermoFisher Scientific, Waltham, USA) 
Eagle’s Minimal Essential Medium (EMEM) supplemented with 10 % Horse Serum (HS) 
MDBK cells 
CvHV2 Viral Stock (4.22 x 105 TCID50/mL, Salla strain) 
Pipettes, pipette-boy, tips 
 
VIRUS INFECTION : 
 
1. Distribute 500 uL of MEM + 10% HS, containing 150,000 cells/well to 24-well plates  
2. Incubate cells for 24 hours to achieve monolayer of MDBK cells 
3. Decant medium from 24-well plates and replace with 500 uL of MEM + 2% HS and 
the concentration of drug to be tested, in all but three wells. 
4. Add 500 uL of MEM to these remaining three wells as a no drug control 
5. Incubate 24-well plates for 1 hour 
6. Create a 10-fold dilution (105-100) of viral stock solution  
7. Create a 10-fold dilution of MEM as a negative control 
8. Inoculate wells with viral dilutions 105-100 and the negative control with three 
replicate wells per dilution  
7. Incubate for 72-hours 
8. Lys cells by freezing 24-well plates at -80C and melting at room temperature.  
9. Repeat 3 times and collect supernatant for use in TCID50 assay. 
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Appendix 4: TCID50 Viral Quantification Assay 
 
DESCRIPTION: Determination of viral titers through 50% Tissue Culture Infective Dose 




96-well plates (Nunc Edge 2.0, ThermoFisher Scientific, Waltham, USA) 
Eagle’s Minimal Essential Medium (EMEM) supplemented with 10 % Horse Serum (HS) 
50 mL Falcon tubes  
1.5 mL Eppendorf tubes 
Trypan blue 
Counting chamber 
Pipettes, pipette-boy, tips 
PBS (phosphate buffered saline) 
Trypsin solution 
3.7 % Formaldehyde 
0.1 % Crystal violet 




Prepare a tenfold dilution from the supernatant of each of the initial viral load solutions (100-105 
TCID50/mL) and negative control solution collected at the end of the experimental infection: 
1) Mark 8 Eppendorf tubes with 1 – 8 
2) Pipette 1080 µL complete EMEM in each tube 
3) Transfer 120 µL of the viral stock (100) to tube 1 (10-1) – mix thoroughly and change the 
tip of the pipette 
4) Then transfer 120 µL from tube 1 to tube 2 and mix. 
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5) Continue until reaching tube 8 (10-8). 
6) Add 100 µL of your diluted virus-suspensions, negative control solution, and EMEM 
(internal control) to the 96 well plate following the layout: 
 
Plate 1: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A (10-1) Negative Control Internal Control 105 105 105 105 104 104 104 104 
B (10-2)             
C (10-3)             
D (10-4)             
E (10-5)             
F (10-6)             
G (10-7)             
H (10-8)             
 
Plate 2: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A (10-1) Negative Control Internal Control 103 103 103 103 102 102 102 102 
B (10-2)             
C (10-3)             
D (10-4)             
E (10-5)             
F (10-6)             
G (10-7)             
H (10-8)             
 
Plate 3: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A (10-1) Negative Control Internal Control 101 101 101 101 100 100 100 100 
B (10-2)             
C (10-3)             
D (10-4)             
E (10-5)             
F (10-6)             
G (10-7)             




7) Prepare cells by subculturing and counting as described in Maintenance of MDBK Cell 
Culture Protocol. 
8) Seed cells in all wells of the 96-well plates at a concentration of 25,000 cells/well in 
aliquots of 100 µL EMEM + 10% HS 
9) Place 96-well plates in the incubator and incubate for 3 hours. 
10) After 3 hours: observe the cells in the microscope to control confluence and adherence. 




1) Remove medium by carefully tipping the 96-well plate over a garbage can and gently 
tapping the back of the plate to fully empty the liquid. 
2) Fix the cells by adding 100 µL/well of a 3.7 % formaldehyde solution for 1 min. 
3) Remove the formaldehyde as in step 1. 
4) Wash with 200 µL PBS/well. 
5) Remove the PBS as in step 1. 
6) Stain the cells by adding 50 µL/well of the crystal violet solution and incubate for 10 
min. 
7) Wash the tray by carefully lowering it in a container full of water and gently moving the 
plate vertically up and down within the water. 
8) Change water and repeat washing until the water no longer turns purple. 
9) Allow plate to completely air draw over several days . 
10) Count using the Reed-Muench method (following page). 
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